Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chau Dang

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
Medicine and Science in Sports and Exercise|March 15, 2024
Mechanisms of Exercise Intolerance Across the Breast Cancer Continuum: A Pooled Analysis of Individual Patient DataJessica M Scott, Jasme Lee, Meghan G Michalski, et al.
Clinical Breast Cancer|October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang, Gabriella D'Andrea, Diana Lake, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer ModelsTung Nguyen Thanh Uong, Meesun Yoon, Ik-Joo Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2026
Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 TrialMario E Lacouture, Alexander Pan, Tara Maier, et al.
Breast Cancer Research and Treatment|March 17, 2006
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspectiveArti Hurria, Shari Goldfarb, Carol Rosen, et al.
NPJ Breast Cancer|November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)Tal Sella, Yue Zheng, Nabihah Tayob, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
Medicine and Science in Sports and Exercise|March 15, 2024
Mechanisms of Exercise Intolerance Across the Breast Cancer Continuum: A Pooled Analysis of Individual Patient DataJessica M Scott, Jasme Lee, Meghan G Michalski, et al.
Clinical Breast Cancer|October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang, Gabriella D'Andrea, Diana Lake, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer ModelsTung Nguyen Thanh Uong, Meesun Yoon, Ik-Joo Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2026
Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 TrialMario E Lacouture, Alexander Pan, Tara Maier, et al.
Breast Cancer Research and Treatment|March 17, 2006
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspectiveArti Hurria, Shari Goldfarb, Carol Rosen, et al.
NPJ Breast Cancer|November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)Tal Sella, Yue Zheng, Nabihah Tayob, et al.
Pageof 8